Ferriprox (deferiprone)
- Region
- 🇪🇺 EU
- Active substance
- deferiprone
- Company
- Chiesi Farmaceutici S.p.A.
- Status
- Authorised
- Therapeutic area
- beta-Thalassemia; Iron Overload
- EU approval
- Wed 25 Aug 1999
- Application
- EMEA/H/C/000236
- ATC
- V03AC02
- Official record
- www.ema.europa.eu
Indication
Ferriprox monotherapy is indicated for the treatment of iron overload in patients with thalassaemia major when current chelation therapy is contraindicated or inadequate. Ferriprox in combination with another chelator is indicated in patients with thalassaemia major when monotherapy with any iron chelator is ineffective, or when prevention or treatment of life-threatening consequences of iron overload (mainly cardiac overload) justifies rapid or intensive correction.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Deferiprone Lipomed Authorised · Lipomed GmbH
- 🇪🇺 Upkanz Application withdrawn · Apotex B.V.
Follow Ferriprox
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.